Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314090 | 0.89 | FGFR1 (0.43) | FGFR1SLC22A6HPRT1POLA1 | |
| SCHEMBL6314097 | 0.87 | FGFR1 (0.42) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6904634 | 0.84 | FGFR1 (0.50) | FGFR1SLC22A6HPRT1PNPPDE4D | |
| SCHEMBL3860484 | 0.77 | FGFR1 (0.50) | FGFR1SLC22A6HPRT1PNPPDE4D | |
| SCHEMBL6902587 | 0.76 | FGFR1 (0.47) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL6902843 | 0.76 | TYMP (0.39) | FGFR1SLC22A6HPRT1TYMPLMNA | |
| SCHEMBL4711405 | 0.75 | FGFR1 (0.58) | FGFR1SLC22A6HPRT1TYMPPNP | |
| SCHEMBL5280050 | 0.74 | FGFR1 (0.57) | FGFR1SLC22A6HPRT1TYMPPOLA1 | |
| SCHEMBL28796542 | 0.73 | FGFR1 (0.54) | FGFR1SLC22A6HPRT1TYMPPDE4D | |
| SCHEMBL6901448 | 0.73 | HPRT1 (0.76) | HPRT1PNPPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050033051-A1 | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | FGFR1 2799/4885SLC22A6 3360/4885HPRT1 871/4885 |
| US-20050033051-A1 | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases | NSUN2, RNASEH1, POLR2H | FGFR1 4136/4885SLC22A6 4025/4885HPRT1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.